Jazz Pharmaceuticals JAZZ Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other accrued liabilities?
- Jazz Pharmaceuticals (JAZZ) reported other accrued liabilities of $66.6M in Q1 2026.
- How has Jazz Pharmaceuticals's other accrued liabilities changed year-over-year?
- Jazz Pharmaceuticals's other accrued liabilities increased by 10.3% year-over-year, from $60.37M to $66.6M.
- What is the long-term trend for Jazz Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's other accrued liabilities has grown at a 18.0% compound annual growth rate (CAGR), from $31.76M to $72.8M.